Investigating Therapeutic Potential of Beta-Glucan on Experimental Toxoplasmosis in Immunocompetent and Immunocompromised Mice: In Silico and in Vivo Studies

Theodor Bilharz Research Institute

Bibliographic Information

Authors: Aboul-Fotouh A.A.; Elfeky F.A.; Omar N.R.; Aboushousha T.; El-Wakil E.S.

Journal: Chemistry and Biodiversity

Publisher: John Wiley and Sons Inc

Publication Date: 22 April 2025

Volume / Issue: Volume 22 / Issue 8

Article No.: e202500370

ISSN: 16121872

DOI: 10.1002/cbdv.202500370

Scopus: View on Scopus

PubMed: 40192266

Document Type: Article

Access: All Open Access; Bronze Open Access


Authors and Affiliations

Aboul-Fotouh A.A., Zoology Department, Faculty of Science for Girls, Al-Azhar University, Cairo, Egypt; Elfeky F.A., Zoology Department, Faculty of Science for Girls, Al-Azhar University, Cairo, Egypt; Omar N.R., Zoology Department, Faculty of Science for Girls, Al-Azhar University, Cairo, Egypt; Aboushousha T., Department of Pathology, Theodor Bilharz Research Institute, Giza, Egypt; El-Wakil E.S., Department of Parasitology, Theodor Bilharz Research Institute, Giza, Egypt


Abstract

There is a need to find efficient treatment for toxoplasmosis, a global disease with a public health concern, as the used therapeutics have limited effectiveness. Beta-glucan (β-glucan), a natural polysaccharide, has anti-inflammatory, immunomodulatory, and anti-infective activities against bacteria, viruses, and parasites. We aimed to investigate the therapeutic efficacy of β-glucan on toxoplasmosis using an in silico study and an in vivo mice model. The β-glucan drug-likeness characteristics were evaluated by molecular docking simulations, Lipinski's RO5 filter analysis, and the computational quantitative structural-activity relationships/absorption, distribution, metabolism, excretion, and toxicity predictive characteristics compared to spiramycin, an anti-toxoplasmosis drug. Sixty albino mice were divided into two divisions, immunocompetent and immunosuppressed. Each division contained five groups; healthy, diseased, spiramycin-treated, β-glucan-treated, and both β-glucan and spiramycin-treated groups. Parasitological, histopathological examinations, and immunological analysis were detected. β-glucan docked complexes demonstrated H-bonding and hydrophobic interactions towards their promising anti-toxoplasmosis targets compared to the spiramycin. The treated mice revealed a statistically significant reduction (p < 0.001) in the parasite burden. Regarding immunocompetent and immunosuppressed division, the group that was treated with both β-glucan and spiramycin, demonstrated the greatest outcomes, with 71% and 66% efficacy, respectively. It is concluded that β-glucan shows promising potential as an anti-toxoplasmosis candidate by potentiating the spiramycin effect and modulating the immunological response. © 2025 Wiley-VHCA AG, Zurich, Switzerland.


Keywords

antiprotozoal agents; drug discovery; T. gondii putative ribose-5-phosphate isomerase; toxoplasmosis; β-glucans; Animals; beta-Glucans; Disease Models, Animal; Female; Immunocompetence; Immunocompromised Host; Mice; Molecular Docking Simulation; Structure-Activity Relationship; Toxoplasma; beta glucan; spiramycin; antiprotozoal agent; animal experiment; animal model; Article; computer model; controlled study; drug absorption; drug distribution; drug excretion; drug metabolism; experimental toxoplasmosis; histopathology; immune response; in vivo study; male; molecular docking; mouse; mouse model; nonhuman; parasite load; parasitology; quantitative structure activity relation; toxicity; animal; chemistry; disease model; drug effect; drug therapy; immunocompromised patient; structure activity relation


Citation Information

Scopus Citations: 3


For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.

The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.

English Website: https://www.tbri.sci.eg/en/

Arabic Website: https://www.tbri.sci.eg/ar/

Prepared and Uploaded by:

Abdalla F. Abdalla

Electronic Portal Unit

Electronic Portal Unit

Popular Posts

A cost-performance index for nano-optical biosensor evaluation: Systematic evaluation of europium–salicylate luminescent platforms for GPC3-targeted early HCC diagnosis

Interpretation of liver stiffness measurement in patients with mixed liver disease etiologies

Multifunctional polycaprolactone-based composite fibers with icariin and glutathione for effective repair of critical-sized bone defects

Holothuria arenicola Extract-Loaded Polycaprolactone Nanocapsules Attenuate Bile Duct Ligation-Induced Acute Liver Injury

Mytilus edulis-mediated green synthesis of selenium nanoparticles with antimicrobial and molluscicidal applications

Microbial levan potentiates hepatic retention and antitumor activity of a PEGylated benzimidazole–curcumin nanocomplex through TLR2–FXR/FGF15-associated immunometabolic remodeling in experimental liver cancer

Variable clinical presentations of pulmonary hydatid cysts: a four-case series from a single center in United Arab Emirates, non-endemic region